Catharina K. Wichers
Utrecht, UT, Netherlands
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 20 publications
Nuclear Receptor Subfamily 4A Signaling as a Key Disease Pathway of CD1c+ Dendritic Cell Dysregulation in Systemic Sclerosis.
Journal: Arthritis & rheumatology (Hoboken, N.J.)
Published: November 18, 2021
Transcriptome Analysis of CCR9+ T Helper Cells From Primary Sjögren's Syndrome Patients Identifies CCL5 as a Novel Effector Molecule.
Journal: Frontiers in immunology
Published: April 29, 2021
Characterization of Long Non-Coding RNAs in Systemic Sclerosis Monocytes: A Potential Role for PSMB8-AS1 in Altered Cytokine Secretion.
Journal: International journal of molecular sciences
Published: March 25, 2021
Hypoxia and TLR9 activation drive CXCL4 production in systemic sclerosis plasmacytoid dendritic cells via mtROS and HIF-2α.
Journal: Rheumatology (Oxford, England)
Published: January 04, 2021
Implication of miR-126 and miR-139-5p in Plasmacytoid Dendritic Cell Dysregulation in Systemic Sclerosis.
Journal: Journal of clinical medicine
Published: December 09, 2020
Longitudinal analysis of T-cell receptor repertoires reveals persistence of antigen-driven CD4+ and CD8+ T-cell clusters in systemic sclerosis.
Journal: Journal of autoimmunity
Published: September 08, 2020
CXCL4 drives fibrosis by promoting several key cellular and molecular processes.
Journal: Cell reports
Published: May 15, 2020
CXCL4 triggers monocytes and macrophages to produce PDGF-BB, culminating in fibroblast activation: Implications for systemic sclerosis.
Journal: Journal of autoimmunity
Published: February 14, 2020
Fatty Acid and Carnitine Metabolism Are Dysregulated in Systemic Sclerosis Patients.
Journal: Frontiers in immunology
Published: December 11, 2019
mTOR inhibition by metformin impacts monosodium urate crystal-induced inflammation and cell death in gout: a prelude to a new add-on therapy?
Journal: Annals of the rheumatic diseases
Published: October 27, 2018
Histone modifications underlie monocyte dysregulation in patients with systemic sclerosis, underlining the treatment potential of epigenetic targeting.
Journal: Annals of the rheumatic diseases
Published: August 16, 2018
Last Updated: 09/26/2026